Drug Trial Radar · NCT05915728
A Study to Compare How Well Gadoquatrane Works and Its Safety With an Already Available Contrast Agent for MRI in People With Any Known or Suspected Problems of the Body (Except Brain or Spinal Cord-related Problems)
Last checked: Nov 19, 2026Latest source record: Aug 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
410
Actual
Start
Jul 24, 2023
Primary completion
May 31, 2024
Study completion Jun 1, 2024
Sponsor
- Lead sponsor
- BayerBayer (BAYRY)
- Sponsor type
- Industry
- First posted
- Jun 23, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Diagnostic
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Researchers are looking for a better way to help people with any known or suspected problems (except brain or spinal cord-related problems) scheduled for a "contrast-enhanced" Magnetic Resonance Imaging (MRI). MRI is used by doctors to create detailed images of the inside of the body to identify health problems. Sometimes doctors need to inject contrast agent into a patient's vein to perform a so called "contrast-enhanced" MRI (CE-MRI). Such CE-MRI examinations may support doctors to identify certain health problems or improve the evaluation. The contrast agents commonly used in MRI are gadolinium-based contrast agents (GBCAs). GBCAs contain a "rare earth" element called gadolinium (Gd). Gadoquatrane is a new contrast agent under development with a lower amount of Gd needed per CE-MRI. The main purpose of this study is to learn whether CE-MRI scans with gadoquatrane work better than MRI scans without the use of a contrast agent (GBCA). The researchers will compare the ability to detect known or suspected problems (except brain or spinal cord-related problems) with gadoquatrane-MRI scans to plain-MRI scans without the use of a contrast agent. The participants will undergo 2 MRI scans, one with gadoquatrane and one with currently used GBCA. Both contrast agents will be injected into the vein. Each participant will be in the study for between 6 and 42 days with up to 7 doctor visits. At the start or during the study, the doctors and their study team will: * take blood and urine samples * do physical examinations * check blood pressure and heart rate * review the MRI scans obtained in the study and decide on the diagnosis * ask the participants questions about how they are feeling and what adverse events they are having. An adverse event is any medical problem that a participant has during a study. Doctors keep track of all adverse events, irrespective if they think it is related or not to the study treatments.
Conditions
- Contrast Enhancement in Magnetic Resonance Imaging
- Non-central Nervous System Pathology
Interventions
Gadoquatrane (BAY1747846)Drug
0.04 mmol Gd/kg body weight, solution for intravenous injection, single dose
GadobutrolDrug
Approved standard of care macrocyclic GBCA, 0.1 mmol Gd/kg body weight, solution for intravenous injection, single dose
Gadoterate meglumineDrug
Approved standard of care macrocyclic GBCA, 0.1 mmol Gd/kg body weight, solution for intravenous injection, single dose
GadoteridolDrug
Approved standard of care macrocyclic GBCA, 0.1 mmol Gd/kg body weight, solution for intravenous injection, single dose
Primary outcomes
What the sponsor says the trial is designed to measure.
- Visualization Parameter Contrast Enhancement Assessed by Separate Blinded Evaluation of Unenhanced and Combined Pre- and Post-gadoquatrane MRI, by a BICRTime frame: 1 day procedure
- Visualization Parameter Delineation Assessed by Separate Blinded Evaluation of Unenhanced and Combined Pre- and Post-gadoquatrane MRI, by a BICRTime frame: 1 day procedure
- Visualization Parameter Morphology Assessed by Separate Blinded Evaluation of Unenhanced and Combined Pre- and Post-gadoquatrane MRI, by a BICRTime frame: 1 day procedure
Locations
85 sites in 16 countries. Site status is shown where the registry gives one.
UAB Hospital - Radiology
Birmingham, Alabama
Halo Diagnostics - Indian Wells
Indian Wells, California
UC Irvine Medical Center
Orange, California
University of Connecticut Health Center
Farmington, Connecticut
Biogenix Molecular, LLC
Miami, Florida
University of Missouri Hospital and Clinic - Neuroradiology
Columbia, Missouri
Duke University School of Medicine - Early Phase Research Unit - Neurology
Durham, North Carolina
Pennsylvania State University College of Medicine
Hershey, Pennsylvania
Houston Methodist Hospital - Cardiology
Houston, Texas
Fundacion Cientifica del Sur | Centro de Lomas de Zamora - Imaging Interventionism Department
Lomas de Zamora, Buenos Aires, Buenos Aires, Argentina
Instituto Alexander Fleming | Sede Central - Departamento de Diagnostico por Imagenes
CABA, Ciudad Auton. de Buenos Aires, Argentina
Sanatorio Otamendi | Imaging Diagnostic Center
Ciudad Autonoma de Buenos Aire, Ciudad Auton. de Buenos Aires, Argentina
Centro de Diagnostico Enrique Rossi | Departamento de Investigacion Clínica
Ciudad Autonoma de Buenos Aire, Ciudad Auton. de Buenos Aires, Argentina
Sanatorio Allende | Departamento de Investigación Clínica
Córdoba, Córdoba Province, Argentina
Clinica Universitaria Reina Fabiola | Consultorios Externos
Córdoba, Córdoba Province, Argentina
Acibadem City Clinic | University Multiprofile Hospital for Active Treatment Tokuda - Radiology Department
Sofia, Bulgaria
University Hospital for Active Treatment Tsaritsa Joanna - ISUL | Radiology Department
Sofia, Bulgaria
University Multiprofile Hospital for Active Treatment Dr Georgi Stranski Pleven | Surgery Department
Pleven, Pleven Province, Bulgaria
Multiprofile Hospital for Active Treatment Central Onco Hospital | Independent Medical Diagnostic Laboratory Mediscan
Plovdiv, Plovdiv Province, Bulgaria
University Multiprofile Hospital for Active Treatment Sveti Georgi | Base II - Imaging Diagnostic Department
Plovdiv, Plovdiv Province, Bulgaria
University Multiprofile Hospital For Active Treatment 'Alexandrovska' EAD
Sofia, Sofia City Province, Bulgaria
University Multiprofile Hospital for Active Treatment 'Sveta Ekaterina' EAD
Sofia, Sofia City Province, Bulgaria
University Multiprofile Hospital for Active Treatment St. Ivan Rilski | Radiology Department
Sofia, Sofia City Province, Bulgaria
Hôpital du Sacré-Cœur de Montréal | Radiology
Montreal, Quebec, Canada
Beijing Chaoyang Hospital, Capital Medical University
Beijing, Beijing Municipality, China
Peking University First Hospital - Oncology Department
Beijing, Beijing Municipality, China
Beijing Hospital
Beijing, Beijing Municipality, China
Nanfang Hospital, Southern Medical University
Guangzhou, Guangdong, China
The First Affiliated Hospital of Jinan University
Guangzhou, Guangdong, China
Huai'an First People's Hospital, Nanjing Medical University
Huai'an, Jiangsu, China
Zhongda Hospital Southeast University
Nanjing, Jiangsu, China
West China Hospital Sichuan University
Chengdu, Sichuan, China
The First Affiliated Hospital of Wenzhou Medical University
Wenzhou, Zhejiang, China
Fakultní nemocnice Ostrava - Radiodiagnostický ústav
Ostrava, Czechia
Nemocnice Pardubickeho kraje, a.s., Pardubicka nemocnice
Pardubice, Czechia
Fakultni nemocnice Plzen - Lochotin
Pilsen, Czechia
Všeobecná fakultní nemocnice v Praze
Prague, Czechia
Fakultní Thomayerova nemocnice - klinicko-farmakologická jednotka
Praha 4 - Krc, Czechia
Fakultní nemocnice Brno - Klinika radiologie a nukleární medicíny
Brno, South Moravian, Czechia
Centre Hospitalier Universitaire de Dijon
Dijon, France
Showing 40 of 85 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.